Item 8.01 Other Events



On January 7, 2020, Cumberland announced the launch of Caldolor® (ibuprofen)
Injection in a ready-to-use bag that may be administered without dilution for
pain relief. This launch follows FDA approval in 2019 of the product's new
delivery method.
A non-steroidal anti-inflammatory drug (NSAID), Caldolor may be used as the sole
method of treatment for mild-moderate pain or as part of a multi-modal treatment
for severe pain. Thus it is positioned to play an important role in combatting
the nation's opioid crisis, which claims the lives of over 130 Americans a day,
according to The Centers for Disease Control and Prevention.
The new formulation of Caldolor comes in a pre-mixed bag containing 800 mg of
ibuprofen in a 200 mL patented low sodium formulation for injection that is
ready to use. It is the first and only FDA-approved pre-mixed bag of ibuprofen.
Caldolor is still available as an 800 mg/8mL single-dose vial (100mg/mL) for
dilution in addition to the ready-to-use bag (4 mg/mL). The new, premixed
presentation provides healthcare professionals a formulation that is easy to
administer, helping manage the treatment of patient pain and fever, while
reducing opioid consumption.
A copy of the press release is furnished as   Exhibit 99.1  .

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses